Studies of the nonspecific cellular immune response in patients with urinary bladder carcinoma. II. Immunodepressive effect of sera from bladder carcinoma. 1979

S Nishio, and A Horii, and Y Morikawa, and J Kawakita, and T Nishijima, and T Kishimoto, and M Maekawa

In vitro reactivity of normal lymphocytes in various sera was determined by quantitation of phytohemagglutinin (PHA)-induced tritiated thymidine incorporation rate (counts per minute). Sera were obtained from normal subjects, fetal calf, and patients with bladder carcinoma. The rate of lymphocyte blastogenesis was expressed as a stimulation index (SI) that was calculated by dividing the number of counts per minute with PHA by that without PHA. The effect of sera on blastogenesis of normal lymphocytes was expressed as percent change (%SI) per SI with fetal calf serum. The SI of normal lymphocytes was similar in autologous serum (26.7 +/- 11.6), fetal calf serum (25.4 +/- 11.8), and heat-inactivated homologous normal AB serum (28.8 +/- 11.4). The SI of normal lymphocytes in sera from patients with bladder carcinoma was significantly lower than in the other two sera (14.0 +/- 7.9). The serum inhibitory effect was significantly associated with the stage and grade of tumor and was diminished after removal of the tumor. The SI of lymphocytes from patients with certain other malignant diseases was significantly lower in autologous serum than in fetal calf serum or homologous normal AB serum. The SI of the lymphocytes from patients with prostatic carcinoma and embryonal cell carcinoma was also low in sera from patients with bladder carcinoma as well as in autologous sera. It is likely that the depressive effect of sera from patients with bladder carcinoma was not specific to bladder carcinoma.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010835 Phytohemagglutinins Mucoproteins isolated from the kidney bean (Phaseolus vulgaris); some of them are mitogenic to lymphocytes, others agglutinate all or certain types of erythrocytes or lymphocytes. They are used mainly in the study of immune mechanisms and in cell culture. Kidney Bean Lectin,Kidney Bean Lectins,Lectins, Kidney Bean,Phaseolus vulgaris Lectin,Phaseolus vulgaris Lectins,Phytohemagglutinin,Hemagglutinins, Plant,Lectin, Kidney Bean,Lectin, Phaseolus vulgaris,Lectins, Phaseolus vulgaris,Plant Hemagglutinins
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D001769 Blood The body fluid that circulates in the vascular system (BLOOD VESSELS). Whole blood includes PLASMA and BLOOD CELLS.
D002295 Carcinoma, Transitional Cell A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS. Carcinomas, Transitional Cell,Cell Carcinoma, Transitional,Cell Carcinomas, Transitional,Transitional Cell Carcinoma,Transitional Cell Carcinomas
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell

Related Publications

S Nishio, and A Horii, and Y Morikawa, and J Kawakita, and T Nishijima, and T Kishimoto, and M Maekawa
May 1986, Hinyokika kiyo. Acta urologica Japonica,
S Nishio, and A Horii, and Y Morikawa, and J Kawakita, and T Nishijima, and T Kishimoto, and M Maekawa
January 1982, Rozhledy v chirurgii : mesicnik Ceskoslovenske chirurgicke spolecnosti,
S Nishio, and A Horii, and Y Morikawa, and J Kawakita, and T Nishijima, and T Kishimoto, and M Maekawa
April 1984, Hinyokika kiyo. Acta urologica Japonica,
S Nishio, and A Horii, and Y Morikawa, and J Kawakita, and T Nishijima, and T Kishimoto, and M Maekawa
June 1980, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
S Nishio, and A Horii, and Y Morikawa, and J Kawakita, and T Nishijima, and T Kishimoto, and M Maekawa
March 1978, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
S Nishio, and A Horii, and Y Morikawa, and J Kawakita, and T Nishijima, and T Kishimoto, and M Maekawa
August 1973, The British journal of cancer. Supplement,
S Nishio, and A Horii, and Y Morikawa, and J Kawakita, and T Nishijima, and T Kishimoto, and M Maekawa
April 1979, Annals of surgery,
S Nishio, and A Horii, and Y Morikawa, and J Kawakita, and T Nishijima, and T Kishimoto, and M Maekawa
May 1978, Clinical immunology and immunopathology,
S Nishio, and A Horii, and Y Morikawa, and J Kawakita, and T Nishijima, and T Kishimoto, and M Maekawa
March 1983, Clinical immunology and immunopathology,
S Nishio, and A Horii, and Y Morikawa, and J Kawakita, and T Nishijima, and T Kishimoto, and M Maekawa
January 1980, Vnitrni lekarstvi,
Copied contents to your clipboard!